The incidence of Kaposi’s sarcoma on HIV-1-infected patients declined in the post-antiretroviral therapy (ART) era. Furthermore, pulmonary Kaposi’s sarcoma constituted a smaller proportion of all Kaposi’s sarcoma patients. The treatment of Kaposi’s sarcoma depends on the disease severity. Chemotherapy with ART is crucial in the treatment of pulmonary Kaposi’s sarcoma. Moreover, paclitaxel and pegylated liposomal doxorubicin are used for the treatment of this disease, and their effects are comparable. Various doses and schedules were adopted by different clinicians. In this study, we present a patient diagnosed with pulmonary Kaposi’s sarcoma, treated with high dose of paclitaxel (200 mg/m2, every 2 weeks) for this disease entity and achieved an excellent outcome.